Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Antithyroid drugs (ATDs) are primarily used as an initial treatment in pediatric patients with Graves’ disease (GD). We aimed to investigate the long-term outcomes in pediatric GD patients receiving ATDs.Methods: Retrospective data from a single center were collected from April 2003 to July 2020. A total of 98 children and adolescents aged 2–16 years diagnosed with GD and receiving ATDs was enrolled. We investigated the factors correlated with remission by comparing children who achieved remission after 5 years and those with persistent disease.Results: The study included 76 girls (77.6%) and 22 boys (22.4%). During the 5-year follow-up period, 18 children (18.3%) maintained remission, ATDs could not be discontinued in 74 patients (75.5%), and relapse occurred in 6 patients (6.2%). The remission group had significantly lower thyroid-stimulating hormone-binding inhibitory immunoglobulin (TBII) level at diagnosis (P=0.002) and 3 months (P=0.002), 1 year (P=0.002), 2 years (P≤0.001), 3 years (P≤0.001), 4 years (P≤0.001), and 5 years (P≤0.001) after ATD treatment than did the nonremission group. The remission group also had a shorter time for TBII normalization after ATD treatment (P≤0.001). Multiple logistic regression analysis showed that the time to TBII normalization (cutoff time=2.35 years) was related to GD remission (odds ratio, 0.596; 95% confidence interval, 0.374–0.951).Conclusion: TBII level and time to TBII normalization after ATD treatment can be used to predict remission in pediatric GD patients.
Abstract
Purpose: Antithyroid drugs (ATDs) are primarily used as an initial treatment in pediatric patients with Graves’ disease (GD). We aimed to investigate the long-term outcomes in pediatric GD patients receiving ATDs.Methods: Retrospective data from a single center were collected from April 2003 to July 2020. A total of 98 children and adolescents aged 2–16 years diagnosed with GD and receiving ATDs was enrolled. We investigated the factors correlated with remission by comparing children who achieved remission after 5 years and those with persistent disease.Results: The study included 76 girls (77.6%) and 22 boys (22.4%). During the 5-year follow-up period, 18 children (18.3%) maintained remission, ATDs could not be discontinued in 74 patients (75.5%), and relapse occurred in 6 patients (6.2%). The remission group had significantly lower thyroid-stimulating hormone-binding inhibitory immunoglobulin (TBII) level at diagnosis (P=0.002) and 3 months (P=0.002), 1 year (P=0.002), 2 years (P≤0.001), 3 years (P≤0.001), 4 years (P≤0.001), and 5 years (P≤0.001) after ATD treatment than did the nonremission group. The remission group also had a shorter time for TBII normalization after ATD treatment (P≤0.001). Multiple logistic regression analysis showed that the time to TBII normalization (cutoff time=2.35 years) was related to GD remission (odds ratio, 0.596; 95% confidence interval, 0.374–0.951).Conclusion: TBII level and time to TBII normalization after ATD treatment can be used to predict remission in pediatric GD patients.
참고문헌 (21)
- 송승민, "한국 소아 및 청소년 Graves병의 자연 경과 및 예후 인자", Clinical and Experimental Pediatrics, 53(4), pp.585~591 (2010), 대한소아청소년과학회
- Weetman AP, "Graves' disease", N Engl J Med, 343, pp.1236~1248 (2000)
- Tomer Y, "Mechanisms of autoimmune thyroid diseases : from genetics to epigenetics", Annu Rev Pathol, 9, pp.147~156 (2014)
- Zimmerman D, "Hyperthyroidism in children and adolescents", Pediatr Clin North Am, 37, pp.1273~1295 (1990)
- 문진수, "2007 한국 소아 청소년 성장도표 : 개발 과정과 전망", Clinical and Experimental Pediatrics, 51(1), pp.1~25 (2008), 대한소아청소년과학회
- Indicators for assessing iodine deficiency disorders and their control through salt iodization, "World Health Organization", World Health Organization, ~ (1994)
- Gastaldi R, "Graves disease in children : thyroid-stimulating hormone receptor antibodies as remission markers", J Pediatr, 164, pp.1189~1194 (2014)
- Smith TJ, "Graves' Disease", N Engl J Med, 375, pp.1552~1565 (2016)
- Magri F, "Gender influences the clinical presentation and long-term outcome of Graves disease", Endocr Pract, 22, pp.1336~1342 (2016)
- Lippe BM, "Hyperthyroidism in children treated with long term medical therapy : twentyfive percent remission every two years", J Clin Endocrinol Metab, 64, pp.1241~1245 (1987)
- Gruñeiro-Papendieck L, "Pediatric Graves' disease : outcome and treatment", J Pediatr Endocrinol Metab, 16, pp.1249~1255 (2003)
- Kaguelidou F, "Graves' disease in childhood : advances in management with antithyroid drug therapy", Horm Res, 71, pp.310~317 (2009)
- 이선희, "소아 및 청소년 그레이브스병 환자에서의 관해 예측 인자와 관해율", Clinical and Experimental Pediatrics, 52(9), pp.1021~1028 (2009), 대한소아청소년과학회
- Glaser NS, "Predictors of early remission of hyperthyroidism in children", J Clin Endocrinol Metab, 82, pp.1719~1726 (1997)
- Glaser NS, "Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study", Pediatrics, 121, pp.e481~e488 (2008)
- Sun Mi Hwang, "Predictive factors for early response to methimazole in children and adolescents with Graves disease: a single-institute study between 1993 and 2013", Annals of Pediatric Endocrinology & Metabolism, 21(2), pp.70~74 (2016), 대한소아내분비학회
- 김신미, "소아 그레이브스병 관해의 예측 지표", Annals of Pediatric Endocrinology & Metabolism, 15(2), pp.100~105 (2010), 대한소아내분비학회
- Schott M, "Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease", Horm Metab Res, 36, pp.92~96 (2004)
- Quadbeck B, "Sensitive thyrotropin and thyrotropinreceptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease", Thyroid, 15, pp.1047~1054 (2005)
- Maugendre D, "Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease", Clin Endocrinol (Oxf), 54, pp.89~96 (2001)
- Zimmermann-Belsing T, "Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease", Eur J Endocrinol, 146, pp.173~177 (2002)